Sign in
Taking people in SpainPhase 1

Tests drug AP-2 in adults with ALS and related brain disorders

Tests the drug AP-2 in adults with ALS or related brain disorders.

Key facts

Who runs it
Molefy Pharma S.L.
Where
Madrid, SpainSee the site
Registry title
The clinical trial to study a new drug, AP-2.
Status
Recruiting
Phase
Phase 1
People taking part
64 people, planned
Started
24 Apr 2026
Expected to end
1 Apr 2027
Type of study
Interventional
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18 to 64 years. It studies a new drug, AP-2, for ALS and related conditions such as frontotemporal dementia and Alexander disease. Healthy volunteers can also join.

Age
18 to 64 years
Sex
Men only

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Spain

  • Hospital Universitario de la PrincesaMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests drug AP-2 in adults with ALS and related brain disordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2025-524480-21-00, who can take part
Record updated
27 October 2026